OPT

OPTHEA FPO [OPT]
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0130 +8.3%

Updated 14 Jul 2026 · Signals refresh every scan

Get alerts when OPT triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track OPT — Free

Active Signals

Bullish Signals

  • RSI is looking oversold — historically a spot where stocks tend to bounce
  • Stochastic just turned bullish from a low level — early reversal sign
  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Drifting lower — down 7.1% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.87, underperforming its peers
  • Critical cash runway (1.0 quarters)
  • Revenue in sharp decline (-100%)
  • Near 52-week low (0% of range)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 97% over the past year
  • Pre-revenue company — Altman Z-Score not applicable
  • Penny stock risk ($0.013)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -100% — the top line is shrinking
  • The bigger volume days are the down days — volume-weighted momentum is negative (-29.91%/day)
Ask Scout AI about OPT
"What's driving OPT today?" "How does OPT compare to peers?" "Key risks for OPT?"
3 free messages/day · Unlimited with Pro

Key Metrics

$17.8M
Market Cap
23.6M
Avg Volume
0.4x
Vol Ratio
$0.01 — $0.60
52-Week Range
N/A
Short Interest
N/A
Cash Runway
N/A
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 84%
LLeader vs LaggardlaggardRS: -58
IInstitutional SponsorshipweakInst: 8%
MMarket DirectionneutralNeutral

Sector: Healthcare

109 tickers in this sector

View all Healthcare signals →
Related Tickers
ECS -20.0%MEM -12.5%NTI +12.5%VBS +11.4%BDX +11.0%
Compare:OPT vs ECSOPT vs MEMOPT vs NTI
Scout Pro — Deeper Analysis for OPT
Try Pro free for 30 days
Share this analysis

Track OPT and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required